6-K
Silence Therapeutics plc (SLN)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OFFOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of November 2021
Commission File Number: 001-39487
Silence Therapeutics plc
(Exact Name of Registrant as Specified in Its Charter)
72Hammersmith Road
London W14 8TH
United Kingdom
(Addressof principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Filed as Exhibit 99.1 to this Report on Form 6-K is a press release of Silence Therapeutics plc, dated November 1, 2021.
Exhibit 99.1 to this Report shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File no. 333-248682) and Form F-3 (File nos. 333-260265 and 333-248203) of the Company (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
| Exhibit<br><br><br>No. | Description |
|---|---|
| 99.1 | Regulatory News Announcement, dated November 1, 2021. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Silence Therapeutics plc | ||
|---|---|---|
| By: | /s/ Mark Rothera | |
| Name: | Mark Rothera | |
| Title: | President and Chief Executive Officer |
Date: November 1, 2021
EX-99.1
Exhibit 99.1
Results of General Meeting
1 November 2021
LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq:SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announces that at its general meeting held today, 1 November 2021, all resolutions set out in the notice of meeting were duly passed on a poll.
The votes were as follows:
| Special Resolution | % | Votesagainst | % | Votes total | % ofISCvoted | Voteswithheld | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 – Approve the cancellation of the admission to trading on AIM of the ordinary shares of<br>nominal value 0.05 each in the capital of the Company and authorise the directors of the Company to take all action reasonable or necessary to effect such cancellation | 31,092,066 | 99.47 | 166,904 | 0.53 | 31,258,970 | 34.82 | 4,408,363 | ||||||
| 2 – Approve, conditional on the passing of Resolution 1, the amendment to the articles of<br>association of the Company | 31,354,885 | 99.89 | 34,007 | 0.11 | 31,388,892 | 35.00 | 4,278,441 |
All values are in British Pounds.
The number of the Company’s ordinary shares in issue as at the date of the meeting was 89,784,720 ordinary shares of nominal value £0.05 each.
A vote withheld is not a vote in law and has not been counted in the total votes or the calculation of the proportion of votes for and against the resolutions.
The Company confirms that, as at today’s date, the timetable for the cancellation of the admission to trading on AIM of the Company’s ordinary shares is as follows:
| Last date for receipt by Link<br>Group from certificated shareholders of duly completed block transfer participation request forms and original share certificates | 3<br>November 2021 at 1.00 p.m. |
|---|---|
| Last date for receipt by The Bank of New York Mellon from CREST<br>holders of duly completed issuance forms | 17 November 2021 at 3.00<br>p.m. |
| Expected date of issuance of ADSs to block transfer<br>participants | 24 November 2021 |
| Expected date of posting of ADS confirmations to shareholders<br>by The Bank of New York Mellon | 24 November 2021 |
| Last day of dealings in the Ordinary Shares on AIM | 29 November 2021 |
| Cancellation of admission to<br>trading on AIM of the Ordinary Shares | 30 November 2021 at 7.00 a.m. |
Enquiries:
| Silence Therapeutics plc<br> <br>Gem Hopkins,<br>Head of IR & Corporate Communications | Tel: +1 (646) 637-3208 |
|---|---|
| Investec Bank plc (Nominated Adviser and Broker)<br><br><br>Daniel Adams/Gary Clarence | Tel: +44 (0) 20 7597 5970 |
| European PR<br> <br>Consilium StrategicCommunications<br> <br>Mary-Jane Elliott/Chris Welsh/Angela Gray<br><br><br>silencetherapeutics@consilium-comms.com | Tel: +44 (0) 20 3709 5700 |
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence’s proprietary mRNAi GOLD^™^ platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence’s wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.